Martin Schrappe Selected Research

T-Cell Antigen Receptors (T-Cell Receptor)

1/2018	Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
12/2014	Detection and management of minimal residual disease in acute lymphoblastic leukemia.
4/2013	Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
5/2006	Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia: comparison of Ig/TCR rearrangements and the genomic fusion gene.
10/2003	Prognostic factors in childhood acute lymphoblastic leukemia.
12/2002	New treatment strategies in childhood acute lymphoblastic leukaemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin Schrappe Research Topics

Disease

115	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 04/2024 - 01/2001
38	Residual Neoplasm 03/2024 - 12/2002
36	Leukemia 03/2024 - 04/2003
27	Neoplasms (Cancer) 02/2024 - 07/2002
25	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 03/2024 - 06/2002
9	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 07/2002
6	Philadelphia Chromosome 07/2023 - 11/2010
6	Pathologic Complete Response 01/2021 - 02/2006
5	Infections 07/2023 - 09/2004
5	Hypersensitivity (Allergy) 06/2023 - 01/2011
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018 - 01/2004
3	Down Syndrome (Down's Syndrome) 01/2020 - 10/2008
3	Hematologic Neoplasms (Hematological Malignancy) 01/2017 - 01/2001
3	T-Cell Leukemia (Leukemia, T Cell) 07/2012 - 11/2008
3	Neuroblastoma 01/2011 - 09/2004
2	Chromosome Aberrations (Chromosome Abnormalities) 11/2022 - 04/2020
2	Aneuploidy (Aneuploid) 08/2021 - 12/2019
2	Brain Neoplasms (Brain Tumor) 01/2021 - 08/2009
2	Second Primary Neoplasms (Neoplasms, Second) 01/2021 - 11/2011
2	Osteonecrosis (Kienbock's Disease) 01/2019 - 10/2018
2	Central Nervous System Diseases (CNS Diseases) 01/2017 - 02/2005
2	Glucocorticoid Receptor Deficiency 04/2010 - 04/2009
1	Leukemic Infiltration 04/2024
1	Graft vs Host Disease (Graft-Versus-Host Disease) 11/2023
1	Heart Arrest (Cardiac Arrest) 07/2023
1	Hyperbilirubinemia 01/2023
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2023
1	Tetraploidy 11/2022

Drug/Important Bio-Agent (IBA)

11	DNA (Deoxyribonucleic Acid)IBA 12/2022 - 12/2002
10	Proteins (Proteins, Gene)FDA Link 04/2024 - 11/2003
10	Prednisone (Sone)FDA LinkGeneric 01/2021 - 11/2003
9	Methotrexate (Mexate)FDA LinkGeneric 12/2023 - 02/2005
9	Asparaginase (Elspar)FDA Link 06/2023 - 01/2011
7	pegaspargase (Oncaspar)FDA Link 12/2023 - 03/2013
7	Imatinib Mesylate (Gleevec)FDA Link 07/2023 - 09/2012
7	Immunoglobulins (Immunoglobulin)IBA 12/2022 - 12/2002
6	GlucocorticoidsIBA 06/2023 - 11/2003
6	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2017
6	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2018 - 12/2002
5	AntibodiesIBA 01/2022 - 01/2011
5	Dexamethasone (Maxidex)FDA LinkGeneric 12/2017 - 06/2002
4	Dasatinib (BMS 354825)FDA Link 04/2024 - 01/2017
4	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 09/2005
3	Transcription Factors (Transcription Factor)IBA 09/2023 - 01/2018
3	blinatumomabIBA 04/2023 - 01/2019
3	Messenger RNA (mRNA)IBA 10/2020 - 05/2010
3	Phosphotransferases (Kinase)IBA 01/2020 - 04/2010
3	Tyrosine Kinase InhibitorsIBA 11/2018 - 03/2014
3	Biomarkers (Surrogate Marker)IBA 10/2018 - 06/2013
3	AntigensIBA 01/2018 - 01/2012
3	Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA 06/2013 - 01/2005
3	EnzymesIBA 11/2011 - 03/2005
2	SteroidsIBA 11/2023 - 07/2010
2	Alemtuzumab (Campath)FDA Link 11/2023 - 11/2013
2	NucleotidesIBA 01/2023 - 11/2015
2	daratumumabIBA 01/2022 - 01/2019
2	MicroRNAs (MicroRNA)IBA 11/2021 - 01/2017
2	ChromatinIBA 01/2020 - 11/2019
2	CytokinesIBA 12/2019 - 10/2008
2	ProteomeIBA 12/2019 - 06/2013
2	Small Interfering RNA (siRNA)IBA 06/2018 - 01/2015
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2017 - 09/2005
2	ruxolitinibIBA 01/2017 - 09/2016
2	Janus Kinase InhibitorsIBA 09/2016 - 10/2008
2	Mercaptopurine (6 Mercaptopurine)FDA LinkGeneric 02/2016 - 03/2005
2	Interleukin-15 (Interleukin 15)IBA 05/2015 - 10/2007
2	Thymidylate SynthaseIBA 06/2013 - 03/2003
2	Interleukin-7 (Interleukin 7)IBA 05/2011 - 06/2002
2	Cytokine Receptors (Cytokine Receptor)IBA 05/2011 - 07/2010
2	dinutuximabIBA 01/2011 - 09/2004
2	Rituximab (Mabthera)FDA Link 07/2010 - 02/2006
2	Cytarabine (Cytosar-U)FDA LinkGeneric 07/2010 - 07/2007
2	thiopurine methyltransferase (thiopurine S-methyltransferase)IBA 08/2009 - 03/2005
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2009 - 01/2001
2	Lymphotoxin-alpha (Lymphotoxin)IBA 06/2009 - 01/2001
2	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 04/2009 - 11/2003
2	Codon (Codons)IBA 01/2005 - 07/2002
1	Pre-B Cell ReceptorsIBA 04/2024
1	ibrutinibIBA 04/2024
1	acalabrutinibIBA 04/2024
1	zanubrutinibIBA 04/2024
1	V 70 (V70)IBA 11/2023
1	gamma-delta T-Cell Antigen Receptors (T-Cell Receptor delta-Chain)IBA 11/2023
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 09/2023
1	BilirubinIBA 01/2023

Therapy/Procedure

63	Therapeutics 03/2024 - 01/2001
34	Drug Therapy (Chemotherapy) 07/2023 - 12/2002
16	Stem Cell Transplantation 07/2023 - 05/2004
14	Hematopoietic Stem Cell Transplantation 01/2023 - 01/2004
7	Radiotherapy 01/2021 - 01/2006
6	Immunotherapy 03/2024 - 05/2004
6	Aftercare (After-Treatment) 01/2021 - 04/2003
5	Transplantation 04/2024 - 06/2008
4	Cranial Irradiation 09/2009 - 01/2004
3	Homologous Transplantation 01/2019 - 06/2008
3	Ligation 11/2015 - 03/2013
3	Remission Induction 11/2013 - 01/2011
2	Induction Chemotherapy 01/2020 - 06/2009
2	Heterologous Transplantation (Xenotransplantation) 01/2020 - 08/2011
2	Combination Drug Therapy (Combination Chemotherapy) 08/2011 - 01/2009